ENTRY       D09926                      Drug
NAME        Icrucumab (USAN/INN)
FORMULA     C6514H10024N1756O2032S42
EXACT_MASS  146704.3296
MOL_WEIGHT  146794.5664
SEQUENCE    (Heavy chain)
            QAQVVESGGG VVQSGRSLRL SCAASGFAFS SYGMHWVRQA PGKGLEWVAV IWYDGSNKYY
            ADSVRGRFTI SRDNSENTLY LQMNSLRAED TAVYYCARDH YGSGVHHYFY YGLDVWGQGT
            TVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP
            AVLQSSGLYS LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA
            PELLGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP
            REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL
            PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT
            VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK
            (Light chain)
            EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY GASSRATGIP
            DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPLTFG GGTKVEIKRT VAAPSVFIFP
            PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
            TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
            (Disulfide bridge: H22-H96, H153-H209, H270-H330, H376-H434, H235-H'235, H238-H'238, L23-L89, L135-L195, H229-L215)
  TYPE      Peptide
EFFICACY    Antineoplastic, Angiogenesis inhibitor, Anti-vascular endothelial growth factor receptor-1 antibody
  TYPE      Monoclonal antibody
COMMENT     Treatment of solid tumors
TARGET      VEGFR1 (FLT1) [HSA:2321] [KO:K05096]
  PATHWAY   hsa04066(2321)  HIF-1 signaling pathway
            hsa04510(2321)  Focal adhesion
BRITE       Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               VEGFR family
                VEGFR1 (FLT1)
                 D09926  Icrucumab (USAN/INN)
DBLINKS     CAS: 1024603-92-6
            PubChem: 124490620
///
